Division of Neurology, Children's Hospital of Philadelphia, USA.
Division of Neurology, Children's Hospital of Philadelphia, USA; Departments of Neurology and Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA; Departments of Anesthesia and Critical Care Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Seizure. 2020 Aug;80:242-248. doi: 10.1016/j.seizure.2020.07.003. Epub 2020 Jul 13.
The ketogenic diet (KD) is initiated emergently in the intensive care unit (ICU) for patients with super refractory status epilepticus (SRSE) and epileptic encephalopathies (EE). However, few data are available regarding safety, effectiveness, and long-term outcomes.
We performed a retrospective cohort study of consecutive patients with KD initiated in the ICU from 2010 to 2018 for SRSE and EE. We characterized time to ketosis, adverse effects, and seizure outcomes. Responders were defined as having ≥50 % reduction in seizure frequency compared to prior to KD initiation.
We identified 29 patients. KD was initiated for SRSE in 12 patients, EE in 8 patients, and EE with SRSE in 9 patients. KD was initiated after a median of 9 days. Ketosis was achieved 2 days faster in fasted patients (p < 0.0001). All patients had at least 1 KD-related adverse effect, most often hypoglycemia, constipation, or acidosis. There was ≥50 % reduction in seizure frequency compared to prior to KD initiation by 1 week in 17/28 patients, seizure-freedom by 2 weeks in 7/28 patients, and weaned off anesthetics in 11/17 patients. All KD-responders at 1 month had continued response at 6 months. Mortality at 1 year was 24 %. There was no difference in KD response or mortality between KD indication groups.
Emergent KD initiation in the ICU is feasible, safe, and often effective for SRSE and EE. Expected adverse effects were common but treatable. Morbidity and mortality in this group was high. A ≥ 50 % reduction in seizure is achieved in most responders by 1-2 weeks.
在重症监护病房(ICU)中,对于患有难治性癫痫持续状态(SRSE)和癫痫性脑病(EE)的患者,紧急启动生酮饮食(KD)。然而,关于安全性、有效性和长期结果的数据很少。
我们对 2010 年至 2018 年期间在 ICU 中因 SRSE 和 EE 而开始 KD 的连续患者进行了回顾性队列研究。我们描述了进入酮症状态的时间、不良反应和癫痫发作结果。反应者定义为与 KD 开始前相比,癫痫发作频率降低≥50%。
我们确定了 29 例患者。12 例患者因 SRSE 开始 KD,8 例患者因 EE 开始 KD,9 例患者因 EE 合并 SRSE 开始 KD。KD 的启动中位数为 9 天。禁食患者的酮症状态更快实现(p <0.0001),提前 2 天。所有患者都至少有一种与 KD 相关的不良反应,最常见的是低血糖、便秘或酸中毒。与 KD 开始前相比,28 例患者中有 17 例在 1 周内癫痫发作频率降低≥50%,28 例患者中有 7 例在 2 周内癫痫发作停止,17 例患者中有 11 例停用麻醉剂。1 个月时的所有 KD 反应者在 6 个月时均有持续反应。1 年死亡率为 24%。KD 反应或死亡率在 KD 适应证组之间没有差异。
在 ICU 中紧急启动 KD 是可行的、安全的,并且对于 SRSE 和 EE 通常是有效的。预期的不良反应很常见,但可以治疗。该组的发病率和死亡率较高。大多数反应者在 1-2 周内达到≥50%的癫痫发作减少。